Xiaoyong Man

29PUBLICATIONS
39CO-AUTHORS
AllergyPainAdolescent healthGene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 03, 2026
Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

|Mar 16, 2026
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.

Xu Yao, Yi Liu, Yang Luo

|Feb 16, 2026
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.

Cheng Zhou, Yan Zhao, Guannan Zhu

|Feb 12, 2026
Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.

Lin Cai, Xiao-Yong Man, Jinyan Wang

|Nov 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.

Yan Zhao, Litao Zhang, Liming Wu

|Oct 13, 2025
Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.

Xue-Yan Chen, Li-Ran Ye, Ni-Chang Fu

Pageof 5

Frequent Collaborators

5 joint publications

Jianzhong Zhang

4 joint publications

Wei Li

2 joint publications

Juan Tao

2 joint publications

Chang-Zheng Huang